Search

Education

PERFORMS: Professional Education for Rural Healthcare Providers Who Care for Multiple Sclerosis Patients

Released On: July 15, 2024
Expires On: July 15, 2025

This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC)
and Catamount Medical Education.

This activity is supported by independent educational grants from
Genentech, Inc. and Novartis Pharmaceuticals Corporation.

Program Description

A two (2)-hour online enduring activity designed to review the most current evidence on multiple sclerosis (MS) care, with a focus on improving care for patients living in rural areas of the United States.

Intended Audience

Neurologists, primary care physicians, nurse practitioners, nurses, PAs, rehabilitation specialists, mental health specialists, pharmacists, and other clinicians in the rural setting who are part of the team that manages patients with multiple sclerosis (MS).

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Review the clinical and paraclinical criteria required for a diagnosis of MS
  • Apply diagnostic criteria in practice to improve the early and accurate diagnosis of MS
  • Review the 2021 MAGNIMS-CMSC-NAIMS Standardized MRI Protocol
  • Employ best practices for the integration of the MAGNIMS–CMSC–NAIMS Consensus Recommendations on the use of MRI in Patients with MS into clinical practice
  • Review clinical, geographic, socio-economic, access to care, and other challenges that can affect the quality of care for MS patients in rural areas
  • Employ strategies to identify and utilize resources, communities of practices, and telehealth to improve the care of MS patients in rural areas
  • Discuss evidence-based principles of disease modification in patients living with MS
  • Apply evidence on disease-modifying therapies to the personalized treatment of MS patients
  • Identify strategies and criteria used to assess treatment response and disease progression
  • Utilize objective data from all members of the healthcare team and patient reported outcomes to assess response to treatment and monitor disease progression
CME/CNE Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Credit Designation
Physician
The CMSC designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
The CMSC designates this activity for a maximum of 2.0 nursing continuing professional development (NCPD) credit (2.0 in the area of pharmacology).

Pharmacists
This knowledge-based activity, JA4008165-9999-24-008-H01-P qualifies for 2.0 contact hours (.20 CEUs) of continuing pharmacy education credit.

Additional Credit Information
All other health care professionals completing this course will be issued a statement of participation.

Faculty and Disclosures

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Gabriel Pardo, MD, FAAN
Director, OMRF Multiple Sclerosis Center of Excellence
Professor, Arthritis and Clinical Immunology Research Program
Oklahoma Medical Research Foundation

Dr. Pardo reports the following relevant financial relationships with ineligible entities:
Consultant: EMD Serono, Inc., Genentech, Inc., Sanofi, TG Therapeutics
Speakers Bureau: Amgen Inc., Bristol-Myers Squibb, EMD Serono, Inc., Genentech, Inc., Novartis Pharmaceuticals Corporation, Sanofi, TG Therapeutics
Contracted Research: Alexion Pharmaceuticals, Biogen, Contineum Therapeutics, EMD Serono, Inc., Genentech, Inc., Novartis Pharmaceuticals Corporation, Sanofi, TG Therapeutics, ViewMind
Ownership Interest: Progentec Diagnostics, Inc.

Activity Staff Disclosures
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have disclosed no relevant financial relationships.

All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at The Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.

The planners, reviewers, editors, staff, CE committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.

Disclosure of Financial Relationships

In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC and Catamount Medical Education require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and Catamount Medical Education mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and Catamount Medical Education seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and Catamount Medical Education are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

Disclosure of Unlabeled Use

CMSC and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

For questions about this activity, please contact Catamount Medical Education at [email protected].